FGFR2 and intrahepatic cholangiocarcinoma: Until recently, the body of literature included important work utilizing engineered cell lines and a single patient-derived ICC cell line with a FGFR2 fusion, lines which were critical to the identification of point mutations as drivers of resistance to targeted therapy17–19.